Clinical Trials in Girona, Spain
3 recruiting
Showing 1–17 of 17 trials
Recruiting
Not Applicable
ALND vs ART in Positive Sentinel Node After Neoadjuvant Therapy in Breast Cancer
Breast CancerRadiotherapy Side EffectSentinel Lymph Node+2 more
Hospital Universitari de Bellvitge820 enrolled59 locationsNCT04889924
Recruiting
Phase 3
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Breast CancerMetastatic Breast CancerAdvanced Breast Cancer+1 more
Olema Pharmaceuticals, Inc.510 enrolled233 locationsNCT06016738
Recruiting
Phase 3
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Prostate Cancer
AstraZeneca700 enrolled328 locationsNCT06952803
Recruiting
Phase 2
A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population
Breast Cancer
MedSIR976 enrolled41 locationsNCT05708235
Recruiting
Phase 2
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
Advanced Breast CancerAdvanced Breast Carcinoma
MedSIR200 enrolled47 locationsNCT06486883
Recruiting
Phase 3
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
AstraZeneca4,300 enrolled727 locationsNCT05774951
Recruiting
Phase 2
Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management
Breast Cancer Stage IV
SOLTI Breast Cancer Research Group300 enrolled27 locationsNCT07371585
Recruiting
Phase 3
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Summit Therapeutics780 enrolled202 locationsNCT06767514
Recruiting
Phase 3
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy
Hot Flashes
Astellas Pharma Global Development, Inc.540 enrolled117 locationsNCT06440967
Recruiting
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Bladder CarcinomaEsophageal CarcinomaNon-small Cell Lung Cancer+13 more
Guardant Health, Inc.2,020 enrolled57 locationsNCT05059444
Recruiting
Phase 3
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
European Organisation for Research and Treatment of Cancer - EORTC220 enrolled94 locationsNCT05512364
Recruiting
An Ophthalmic Safety Study in Patients With Breast Cancer
Ophthalmic Safety in Patients With Breast Cancer
AstraZeneca160 enrolled75 locationsNCT06767462
Recruiting
Phase 3
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
AstraZeneca5,500 enrolled794 locationsNCT05952557
Recruiting
Long-Term Follow-up Study of Early Stage Breast Cancer Patients Included in GEICAM Studies
Invasive Breast Cancer Early Stages
Spanish Breast Cancer Research Group8,000 enrolled73 locationsNCT03390894
Recruiting
Phase 2
Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy
Fundación GECP19 enrolled20 locationsNCT05398094
Recruiting
Phase 3
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
CarcinomaNon-Small-Cell Lung
AstraZeneca324 enrolled283 locationsNCT05261399
Recruiting
The Impact of Radiotherapy on Oligometastatic Cancer
Metastatic Breast CancerMetastatic Lung CancerMetastasis+2 more
Institut Investigacio Sanitaria Pere Virgili2,000 enrolled21 locationsNCT05933876